Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437203 · ClinicalTrials.gov registry record · Phase 1
PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT00437203 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 43 participants.
The verdict
NCT00437203, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
To determine the overall safety of PF-00477736 when given in combination with gemcitabine, a chemotherapy agent, in patients with advanced solid tumors and determine the maximum dose of PF-00477736 that can be safely given in combination with gemcitabine. This is the first study of PF-00477736 in humans.
Interventions
- DRUG gemcitabine
- DRUG PF-00477736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00437203
The ClinicalTrials.gov registry entry for NCT00437203 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine is the first listed.
NCT00437203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00437203 about?
NCT00437203 is a clinical study titled "PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine". To determine the overall safety of PF-00477736 when given in combination with gemcitabine, a chemotherapy agent, in patients with advanced solid tumors and determine the maximum dose of PF-00477736 that can be safely given in combination with gemcitabine. This is the first study of PF-00477736 in hu...
What is the current status of trial NCT00437203?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2006-12. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00437203?
The interventions under investigation include: gemcitabine (DRUG), PF-00477736 (DRUG).
Who is sponsoring clinical trial NCT00437203?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.